T1	Disease	68 96	non-small cell lung cancer (
T2	Disease	97 114	NSCLC ) confirmed
T3	Pharmacodynamic_phenotype	128 145	response rate and
T4	Phenotype	146 174	progression-free survival of
T5	Gene_or_protein	181 248	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor
T6	Chemical	181 257	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor as first
T7	Chemical	285 309	chemotherapy in patients
T8	Limited_variation	341 342	.
R1	isEquivalentTo	Arg1:T1	Arg2:T2
R2	isEquivalentTo	Arg1:T2	Arg2:T1
R3	increases	Arg1:T2	Arg2:T3
R4	increases	Arg1:T2	Arg2:T4
R5	increases	Arg1:T3	Arg2:T4
R6	isAssociatedWith	Arg1:T4	Arg2:T2
R7	isAssociatedWith	Arg1:T4	Arg2:T3
R8	isAssociatedWith	Arg1:T4	Arg2:T8
R9	treats	Arg1:T5	Arg2:T1
R10	treats	Arg1:T5	Arg2:T2
R11	increases	Arg1:T5	Arg2:T3
R12	increases	Arg1:T5	Arg2:T4
R13	influences	Arg1:T5	Arg2:T6
R14	treats	Arg1:T5	Arg2:T8
R15	treats	Arg1:T6	Arg2:T1
R16	treats	Arg1:T6	Arg2:T2
R17	increases	Arg1:T6	Arg2:T3
R18	increases	Arg1:T6	Arg2:T4
R19	influences	Arg1:T6	Arg2:T5
R20	treats	Arg1:T6	Arg2:T8
R21	treats	Arg1:T7	Arg2:T1
R22	treats	Arg1:T7	Arg2:T2
R23	influences	Arg1:T7	Arg2:T5
R24	influences	Arg1:T7	Arg2:T6
R25	isAssociatedWith	Arg1:T7	Arg2:T8
R26	isAssociatedWith	Arg1:T8	Arg2:T2
R27	influences	Arg1:T8	Arg2:T4
R28	influences	Arg1:T8	Arg2:T5
R29	influences	Arg1:T8	Arg2:T6
R30	isAssociatedWith	Arg1:T8	Arg2:T7
